Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Recruiting · NCT02393157 · Registry updated 2025-08-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma, viral infectious disease | Recruiting | Phase 2 | 2025-08-08 | NCT02393157 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| New York Medical College | 28 |
| Roswell Park Cancer Institute | 92 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| New York Medical College | Valhalla | United States | 71 |